Earlier Intervention in the Management of Hypercholesterolemia What Are We Waiting For? by Steinberg, Daniel
A
e
p
b
r
f
n
F
T
c
t
h
2
m
a
p
b
w
p
a
F
m
i
t
L
s
p
o
F
b
F
C
Journal of the American College of Cardiology Vol. 56, No. 8, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PVIEWPOINTS AND COMMENTARY Viewpoints
Earlier Intervention in the
Management of Hypercholesterolemia
What Are We Waiting For?
Daniel Steinberg, MD, PHD
La Jolla, California
The thesis advanced here is that we are initiating treatment of hypercholesterolemia (and other risk factors) too
late in life. Initiating treatment at, for example, age 30 years instead of age 60 years might very well prevent not
just 30% of events, as in the 5-year statin trials, but perhaps as many as 60%. (J Am Coll Cardiol 2010;56:
627–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.057b
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S30-year-old man is referred because of hypercholesterol-
mia (total cholesterol, 240 mg/dl). His high-density li-
oprotein cholesterol (HDL-C) is 45 mg/dl, and his systolic
lood pressure is 135 mm Hg. He is a smoker and has
epeatedly tried to quit, without success. He has a negative
amily history for coronary heart disease (CHD), and he has
o other risk factors. These numbers put his 10-year
ramingham risk at 6%. According to current ATP (Adult
reatment Panel) III guidelines, drug treatment of hyper-
holesterolemia in this man would be inappropriate (1).
Now let’s move the clock forward 30 years and assume
hat the numbers above remain exactly the same, except that
e is now 60 years old. His Framingham 10-year risk is now
0%, and now he does qualify for immediate drug treat-
ent. In the intervening 30 years, the extent of his coronary
therosclerosis has been relentlessly increasing, and the
robability that 1 of those maturing lesions will rupture has
een increasing along with it. We have lost 30 years during
hich it might have been possible to significantly slow
rogression and improve the chances that this man could
void a myocardial infarction.
The crucial point here is that the 6% estimated 10-year
ramingham risk at 30 years of age in our example above is
isleading. That figure may correctly predict the risk for the
mmediately following 10 years but fails to take into account
hat the risk is going to increase progressively as he ages.
loyd-Jones et al. (2) have made a persuasive case for
witching from 10-year risk to lifetime risk, namely, the
robability that a person will die of coronary disease sooner
r later. They point out that for men 40 years of age in the
ramingham cohort whose plasma cholesterol level was
etween 200 and 239 mg/dl, the 10-year risk was only 5%,
rom the Department of Medicine, University of California San Diego, La Jolla,u
alifornia. Dr. Steinberg has been a consultant for Merck.
Manuscript received November 29, 2009; accepted December 16, 2009.ut lifetime risk was 43%. In other words, eventually almost
0% of these hypercholesterolemic men are going to die of
HD!
ill starting treatment earlier really help? The lesions of
therosclerosis begin in childhood. Fatty streaks were found
n the coronary arteries of more than a third of our Korean
ar casualties, average age 22 years (3). Raised lesions are
ound in the coronary arteries of 37% of healthy organ
onors age 20 to 29 years (4). These lesions are themselves,
f course, clinically benign but “the fatty streak is the father
f the fatty plaque,” as shown in the landmark national
tudy Pathological Determinants of Atherosclerosis in the
oung (5). The point is that if we could prevent the
ormation of the fatty streaks, there might not ever be
laques to worry about—or at least fewer of them. Is that a
easonable expectation? Well, the major risk factors that
redict the extent of fatty streaks in children are exactly the
ame as those that predict the probability of infarction in
dults: hypercholesterolemia, cigarette smoking, and hyper-
ension (6,7). In short, atherosclerosis begins early and stays
ate. It is the same disease over the decades, albeit with
tructural characteristics and composition evolving with
ime. Thus, there is good reason to believe that intervention
arly in the game would reduce the chances that the stage of
ulnerable plaque would ever be reached.
This paper will focus on the evidence supporting earlier
ntervention on hypercholesterolemia, but it should be
tressed that much of the same reasoning applies to obesity,
igarette smoking, hypertension, diabetes mellitus, and
ther reversible risk factors. If and when imaging techniques
llow us to measure quantitatively the burden of early
esions, we will then have an additional tool for assessing
isk early on.
mportant new genetic evidencemandating early intervention.
ome new indirect but powerful genetic evidence tells
s how great the impact of early intervention might be.
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Earlier Intervention: What Are We Waiting For? August 17, 2010:627–9Cohen et al. (8) have shown that
having a low level of low-density
lipoprotein (LDL), not just for
the canonical 5 years of most
intervention studies, but for a
lifetime, confers much more pro-
tection against CHD than statin
treatment in the 5-year clinical
rials (8). The recently discovered PCSK9 gene plays an
mportant role in regulating the level of expression of the
DL receptor. Loss-of-function mutations in this gene in
frican Americans cause the plasma LDL level to be lower
y 28% than in the general African-American population.
pproximately 2% of African Americans carry this muta-
ion, enough to allow meaningful epidemiologic studies.
ow, a 28% drop in LDL in a 5-year statin trial would be
ssociated with a 25% to 35% drop in CHD risk. In
ontrast, this 28% drop in LDL from birth was associated
ith a startling 88% drop in CHD risk (8).
These remarkable findings have been confirmed and
xtended (9,10). Gain-of-function mutations of PCSK9
ecrease expression of the LDL receptor and result in a
henotype closely resembling familial hypercholesterolemia
11). Assuming that the only function of PCSK9 is to
egulate LDL levels (i.e., that the decrease of CHD is
irectly attributable to the LDL lowering), it should be
ossible in principle to see much more than a 30% decrease
n CHD risk if we treated earlier. How early? Few would
ropose starting drug treatment at birth, but for persons at
ery high risk, it should be started not too long after that,
nd perhaps it should be started very early even for those at
oderately high risk. With early intervention, the degree of
DL lowering might not have to be as great as what we aim
or when intervention is started late in life. Hence, the doses
f drugs or the strictness of diet necessary to achieve goal
evels might be less of a problem. Early intervention on
ther reversible risk factors would probably amplify the
enefit.
hy then are we not treating at an earlier age? If there
ere a drug that could correct hypercholesterolemia cheaply
nd with zero risk of adverse effects, we might already be
dding it to our drinking water. But no drug is totally free
f side effects. Even the statins, possibly the safest of drugs
ffective in treating a chronic degenerative disease, have side
ffects, and the cost, while dropping significantly, is not
ero. Then why don’t we start some large-scale, double-
linded, randomized clinical trials to directly compare
ffectiveness of treatment starting at 30 years of age with
ffectiveness of treatment started at 60 years of age?
First, event rates being so much lower in younger sub-
ects, the number we would have to enroll would be in the
ens of thousands, very possibly 100,000. Second, the
osts of the study would be astronomical. Such a study will
robably never be done. In the 1960s, the National Heart
nstitute realized that it was critical to settle the debate
Abbreviations
and Acronyms
CHD  coronary heart
disease
LDL  low-density
lipoproteinbout the role of dietary fat in CHD. An executive com- cittee under the chairmanship of E. H. Ahrens was given
unds to do a feasibility study. They concluded that the
-year study would require the recruitment of 50,000 to
00,000 men age 40 to 59 years, and that it would require
lmost the entire Institute budget for 5 years (12). It was
ever done. A 30-year coronary prevention trial in a general
opulation will probably never be done.
f the definitive randomized clinical trial is out of the
uestion, what are we to do? One option is to say that in
he absence of a clinical trial, we cannot be certain that early
reatment will be safe and effective, and therefore our hands
re tied. That would be the conservative and conventional
hing to do. But starting earlier might very well increase
alvage rate from the 30% seen in the 5-year statin trials to
s much as 60% (extrapolating from the PCSK9 findings). It
s predicted that about 800,000 Americans will have a new
oronary attack in 2009 (13). If this annual rate continues at
he same pace, statin treatment under current guidelines
ay eventually reduce it by 30% (prevent about 240,000
vents), but starting treatment much earlier might prevent
s much as 60% of events—480,000 myocardial infarctions.
n other words, a decision to not start earlier might mean
llowing about 240,000 coronary events to occur annually
hat could have been prevented.
The second option is to say that the strength of the
vidence for the lipid hypothesis is sufficiently robust to
ustify extrapolating and proceeding without the clinical trial
the trial that will never be done). Many different lines of
vidence support the lipid hypothesis, ranging from animal
odel studies, through epidemiologic correlations, patho-
ogic observations, and mechanistic studies (14,15). Most
mportantly, the remarkable results of the statin intervention
rials, in the general population and in almost every sub-
opulation studied, leave no doubt that lowering cholesterol
evels reduces risk. What are we waiting for?
ow Early Do We Start?
s always, the devil is in the details, and the answer will vary
ccording to the cardiovascular risk of those to be treated. We
lready treat those at extremely high risk (e.g., familial hyper-
holesterolemia) in childhood. At the other end of the spec-
rum, we might not want to intervene at any age for persons
ith very low lifetime risk. An opening bid for discussion
ight be this: start treatment at 30 years of age for anyone with
lifetime risk of 35% or more. Much animated discussion will
ndoubtedly follow.
Obviously, very careful thought must be given to any risks
hat might be involved. For example, long-term safety
valuations lasting not just months but years might be
equired for any regimen proposed for use in younger
roups. Expert panels need to go into the details and decide
hat approaches the available science supports. I think wean do better. What are we waiting for?
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